Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis

AIM: The Certolizumab–Optimal Prevention of joint damage for Early Rheumatoid Arthritis (C‐OPERA) study demonstrated that in methotrexate (MTX)‐naïve early RA patients with poor prognostic factors, 1‐year certolizumab pegol (CZP) therapy added to the first year of 2‐year optimized MTX therapy brings...

Full description

Saved in:
Bibliographic Details
Published in:Int J Rheum Dis
Main Authors: Tanaka, Yoshiya, Atsumi, Tatsuya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Shoji, Toshiharu, Miyasaka, Nobuyuki, Koike, Takao
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065202/
https://ncbi.nlm.nih.gov/pubmed/31957303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.13780
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items